In Vivo Tumor Growth Control by General Control Nonderepressible 2-Targeting Agents Results from Kinase Activation

Area of Science:

• Molecular Biology
• Cellular Signaling
• Cancer Research

Background:

• General Control Nonderepressible 2 (GCN2) kinase is crucial for the integrated stress response (ISR) under nutrient stress.
• GCN2 inhibition shows promise for cancer therapy by inducing apoptosis and inhibiting tumor growth.
• Previous studies suggest GCN2 inhibition is ineffective without nutrient stress.

Purpose of the Study:

• To investigate the dual role of GCN2 inhibitors at varying concentrations.
• To elucidate the mechanism by which GCN2-targeting agents affect tumor cell viability and growth.
• To clarify the clinical development landscape for GCN2-targeting compounds.

Main Methods:

• Screening of multiple GCN2 inhibitors across various concentrations.
• Biochemical and cell-based assays to assess GCN2 activity.
• In vitro and in vivo studies using knockdown/knockout models and ISRIB treatment.
• Analysis of apoptosis markers (cleaved caspase 3, cleaved PARP).

Main Results:

• Multiple GCN2 inhibitors activate GCN2 at low concentrations and inhibit at high concentrations.
• GCN2 activation, not inhibition, correlates with decreased in vitro viability and in vivo tumor growth inhibition.
• GCN2-dependent ISR activation is essential for the observed effects, confirmed by ISRIB treatment.
• Activating doses induce apoptosis markers, while non-activating agents show no impact on viability.

Conclusions:

• GCN2 activation by specific agents, rather than inhibition, is key to anti-tumor effects.
• The findings highlight the importance of concentration-dependent effects for GCN2-targeting drugs.
• This study provides critical insights for optimizing GCN2-targeted cancer therapies.